Transcatheter closure of moderate-to-large patent ductus arteriosus in infants using Amplatzer duct occluder.
(19/221)
BACKGROUND: There are difficulties in transcatheter closure of patent ductus arteriosus (PDA) in infants. METHODS AND RESULTS: The 46 infants (mean age 6.2+/-2.7 months; mean body weight 6.3+/-1.6 kg) who underwent PDA closure using the Amplatzer duct occluder (ADO). The indication for using an ADO was a ductus diameter > or =2.5 or 3 mm. Device diameter selected was 1-3 mm larger than ductal diameter. The mean systolic pulmonary artery pressure was 40.9+/-18.2 mmHg. The mean Qp/Qs ratio was 3.1+/-1.2. The mean ductus diameter was 3.3+/-0.8 mm. ADO was successfully deployed in 45 patients. Failure occurred in 1 case. The mean diameter of device used was 5.4+/-1.1 mm. No severe complications occurred. At the 1-month echocardiographic follow-up, a small residual shunt was present in 4 of 45 patients and had disappeared in all 4 patients at the 3-month follow-up. One patient developed a moderate degree of left ventricular outflow tract obstruction 2.3 years after the procedure. CONCLUSIONS: Transcatheter closure of PDA in infants using the ADO is a safe and effective method. (+info)
Management of a pulsatile mass coming through the sternum. Pseudoaneurysm of ascending aorta 35 years after repair of tetralogy of Fallot.
(20/221)
Successful interventional treatment of a retrosternal pseudoaneurysm of the ascending aorta with an Amplatzer Vascular Plug II.
(22/221)
Pseudoaneurysm of the aorta is a rare, but potentially dangerous complication after cardiac surgery, trauma or infective aortitis. Potential fatal risk of rupture with severe hemorrhage exists, so that treatment is necessary. Surgical management carries a high morbidity and mortality rate. Using an endovascular transcatheter method seems to be a promising option for treatment of aortic pseudoaneurysms. We report a case of ascending aortic pseudoaneurysm, which was diagnosed 11 years after cardiac surgery and treated successfully by implantation of an Amplatzer Vascular Plug II. (+info)
Percutaneous PFO closure using the Premere device occluder: initial experience.
(23/221)
INTRODUCTION: Most data on percutaneous closure of patent foramen ovale (PFO) relate to devices not specifically designed for this pathology. OBJECTIVE: Our aim in this article is to share our initial experience with the Premere PFO closure system. METHODS: In our hospital 14 consecutive patients presenting cryptogenic stroke underwent percutaneous closure using this device. The device was successfully implanted in 11 of the 14 patients (78.5%). Implantation was impossible in three patients because of a significant atrial septal aneurysm (ASA) or a multiperforated septum. RESULTS: Mean clinical and echocardiographical follow-up was 7 +/- 7 months. A residual shunt was seen in only one patient (9%) three months after device implantation. During follow-up, no device-related complications were observed, such as device thrombosis or fistula. None of the patients presented other significant clinical events such as strokes or arrhythmia. CONCLUSION: According to our experience the Premere is a secure and reliable device for PFO closure, but patients must be selected carefully for implantation to exclude those presenting significant ASA. (+info)
Endovascular repair of a type B aortic dissection with a ventricular septal defect occluder.
(24/221)